The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

March 2021

All Providers

Blue Cross and BCN educate members about the COVID‑19 vaccine

Blue Cross Blue Shield of Michigan and Blue Care Network are encouraging members to obtain the COVID‑19 vaccine when they have the opportunity to do so. Here’s how we’re communicating with our members about the vaccine:

These communications are designed to allay concerns about obtaining the vaccine and answer questions about cost and access. We encourage you to connect with your patients who are eligible to receive the vaccine to answer any questions they may have.

We told you in our February issue that Blue Cross and BCN members have no out‑of‑pocket costs for obtaining the COVID‑19 vaccine. We also have information on vaccines for providers on our Coronavirus (COVID‑19) information updates for providers webpages within our secure provider website, as well as on our public website at bcbsm.com/coronavirus. Quick billing information can be found in our COVID‑19 vaccine billing information at a glance document.


We’re migrating to a new platform for electronic transmissions

Blue Cross Blue Shield of Michigan is moving to a new SFTP file transfer platform, Edifecs, for your electronic transmissions (such as 837 claims, 277CA transactions and reports, 835 ERA, 999 acknowledgements and capitation reports).

We plan to retire the current SFTP file transfer platform, EDDI, this year. To ensure there are no interruptions to your claim submissions, we ask that you follow the migration schedule provided to you.
If you haven’t received it already, an email with your migration schedule will be coming from your assigned support representative at EDIMigration@bcbsm.com. We’re using a phased migration schedule that will extend through the end of April.

  • Your email subject will be: Update: New EDI File Transfer Platform (XX)
  • (XX) is the initials of your EDI migration support representative.
  • From: EDImigration@bcbsm.com

We’re attaching a Technical Info Sheet and FAQ document to the email so you’ll know what actions you’ll need to take.

If you have any questions about this move, email EDIMigration@bcbsm.com.

Note: If any of your information has changed (email, vendors, contact information, etc.), email us at EDIMigration@bcbsm.com so we can update it as soon as possible. Include your submitter ID with your inquiry.


Get ready for Availity: How to use new search feature

Online provider toolsWhen Blue Cross Blue Shield of Michigan and Blue Care Network move to the Availity® provider portal later in 2021, you’ll notice some updated features that will help you find what you need faster. Here’s a preview of the search capability that will be available on Availity.

Availity has a keyword search field in the upper right corner of the page. Here are some of the items you can find using the search feature:

  • Specific content either available to all or posted within Payer Spaces (areas with content specific to a certain health plan, like Blue Cross and BCN)
  • An application
  • Key help topics, tips and quick links to Availity training
  • Diagnosis and procedure codes

Note: You can find them by code or a portion of the code name.

The search feature isn’t case sensitive, but you’ll need to spell the word correctly for the system to find what you’re searching for. So, if you remember seeing a resource or an announcement, but don’t remember where it was, type in a keyword and Availity will help you find it.

Search feature screenshot

Questions?
If you have questions about the move to Availity, check our Frequently Asked Questions document first. If your question isn’t already answered there, submit your question to ProviderPortalQuestions@bcbsm.com, so we can consider adding it to the FAQ document.

If you need immediate assistance or have a question specific to a certain member or situation, use our website resources or contact Provider Inquiry.

 Web resources:

  • Log in as a provider at bcbsm.com.
  • Find prior authorization information for Michigan providers at ereferrals.bcbsm.com.
  • Find prior authorization information for non-Michigan providers and medical policy information by going to bcbsm.com/providers and clicking on Quick Links.

Provider Inquiry numbers are available at bcbsm.com/providers. Click on Contact Us. Then click on the type of provider you are, and click on Provider Inquiry.

Call the Blue Cross Web Support Help Desk at 1‑877‑258‑3932 if you have problems with the current Blue Cross provider portal.

Previous articles about Availity
We’re providing a series of articles focusing on our move to Availity for our provider portal. Here are the articles we’ve already published, in case you missed them:


Blue Cross and BCN to collaborate with OptumRx for pharmacy benefit management services

Blue Cross Blue Shield of Michigan, Blue Care Network and OptumRx will be working together to give members, health care providers and employers prescription drug benefit services that are expected to improve the pharmacy experience, drive better health outcomes and lower costs. The collaboration will take effect Jan. 1, 2022, for commercial individual and group members, and Jan. 1, 2023, for Medicare Advantage individual and group members.  

As a leading pharmacy care services provider, OptumRx will augment Blue Cross’ existing programs, bringing new tools and digital technology designed to better manage the overall drug spend and increase member engagement in pharmaceutical treatment. The OptumRx integrated health and wellness service platform complements Blue Cross’ integrated benefit solutions. Through this collaboration, OptumRx will support administration of pharmacy claims, manage rebate contracting with pharmaceutical manufacturers, provide mail-order dispensing and manage Blue Cross’ pharmacy networks.

“Holding the line on steadily increasing pharmacy costs and ensuring members have access to the prescriptions they need are top priorities for Blue Cross,” said Blue Cross President and CEO Daniel J. Loepp. “We’re confident our collaboration with OptumRx will help us move closer to reaching those goals through affordable, innovative solutions that improve care within our communities.”

The collaboration advances Blue Cross’ commitment to providing members with convenient and affordable access to prescription medications, with no disruption to current members, through a comprehensive retail and home delivery pharmacy network. Leveraging OptumRx’s expertise, negotiated contracts and network of more than 68,000 pharmacies, this collaboration will expand access and significantly improve prescription drug pricing and rebates, offering members and group customers more value and cost savings.

OptumRx will provide enhanced customer service technology integrated with member communications to ensure a smooth exchange of information. An updated website and new mobile app will also place individualized coverage details at each member’s fingertips for quick and convenient access to cost and benefit information. Blue Cross will continue to work closely with its current pharmacy benefit provider, Express Scripts Inc., to ensure a successful and seamless transition.

We’ll provide more details later in the year as we get closer to the transition date.


New members to be issued alphanumeric subscriber IDs starting Feb. 27

We’ll issue alphanumeric subscriber IDs to all new Blue Cross Blue Shield of Michigan and Blue Care Network members, starting Feb. 27, 2021. The start date was communicated in a web‑DENIS message posted Feb. 24.

We announced in the June Record that we’d be transitioning to alphanumeric IDs this year, but the start date wasn’t available at that time.

We’ll use the letter M after the prefix to begin the alphanumeric ID, followed by eight numbers. For example, a new subscriber ID could look like this: XYZM91234567. When you see one of these ID cards and check benefits and eligibility on web‑DENIS, you’ll enter the last nine characters of the subscriber ID.

These de‑identified IDs are being used to avoid duplication with subscribers’ Social Security numbers, align with other health plans and automate manual processes previously used when correcting duplicate numbers.

There are currently no plans to change subscriber IDs for existing members.


Check for messages in e‑referral to finalize your pending requests

You can help us complete the processing of your requests for authorization — and improve turnaround time — by checking the e-referral system for messages and responding quickly. We may reach out to you using the Case Communication feature in e-referral for additional information, including clinical documentation, that we need to process your requests.

Refer to the e‑referral User Guide sections about case communication for instructions.


CPT and HCPCS update

There’s been a change in the coverage decision and benefit category for HCPCS code C9770 and a change in coverage for CPT code *55880 since we communicated about the codes in the February Record.

Following is updated information:

Code Category Coverage comments Effective date
C9770

Surgery

Covered

Jan. 1, 2021


Code Category Coverage comments Effective date
*55880

Surgery

Covered

Jan. 1, 2021


HCPCS replacement codes established

J1823 replaces J3490 and J3590 when billing for Uplizna (inebilizumab‑cdon)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Uplizna® (inebilizumab‑cdon).

All services through Dec. 31, 2020, will continue to be reported with codes J3490 and  J3590. All services performed on and after Jan. 1, 2021, must be reported with J1823.

Prior authorization is required for all groups unless they are opted out of the prior authorization program.

For groups that have opted out of the prior authorization program, this code is covered for the FDA‑approved indications.
 
Site of care prior authorization is required through the Medical Benefit Drug Program.

J7352 replaces J3490 and J3590 when billing for Scenesse (afamelanotide injectable implant)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Scenesse (afamelanotide injectable implant).

All services through Dec. 31, 2020, will continue to be reported with codes J3490 and J3590. All services performed on and after Jan. 1, 2021, must be reported with J7352.

Prior authorization is required for all groups unless they are opted out of the prior authorization program.

For groups that have opted out of the prior authorization program, this code is covered for the FDA‑approved indications.

J9144 replaces J3490, J3590 and C9062 when billing for Darzalex FasPro (daratumumab and hyaluronidase-fihj)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Darzalex FasPro™ (daratumumab and hyaluronidase‑fihj).

All services through Dec, 31, 2020, will continue to be reported with codes J3490 and J3590. Facilities can continue to report C9062 through Dec. 31, 2020. All services performed on and after Jan. 1, 2021, must be reported with J9144.

J9223 replaces J3490 and when billing for Zepzelca (lurbinectedin)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Zepzelca (lurbinectedin).

All services through Dec. 31, 2020, will continue to be reported with code J3490. All services performed on and after Jan. 1, 2021, must be reported with J9223.

J9281 replaces J9999 and C9064 when billing for Jelmyto (mitomycin)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Jelmyto™ (mitomycin).

All services through Dec. 31, 2020, will continue to be reported with code J9999 and facilities can continue to report C9064 through Dec. 31, 2020. All services performed on and after Jan. 1, 2021, must be reported with J9281.

J9316 replaces J3590 when billing for Phesgo (pertuzumab, trastuzumab and hyaluronidase‑zzxf)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Phesgo (pertuzumab, trastuzumab and hyaluronidase‑zzxf).

All services through Dec. 31, 2020, will continue to be reported with code J3590. All services performed on and after Jan. 1, 2021 must be reported with J9316.

J9317 replaces J3590 and C9066 for Trodelvy (sacituzumab govitecan‑hziy)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Trodelvy™ (sacituzumab govitecan‑hziy).

All services through Dec. 31, 2020, will continue to be reported with code J3590. Facilities can continue to report C9066 through Dec. 31, 2020. All services performed on and after Jan. 1, 2021, must be reported with J9317.

S0013 replaces J3490 and J3590 when billing for Spravato (esketamine)

The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Spravato® (esketamine).

All services through Dec. 31, 2020, will continue to be reported with codes J3490 and J3590. All services performed on and after Jan. 1, 2021, must be reported with S0013.

Prior authorization is required for all groups unless they are opted out of the prior authorization program.

For groups that have opted out of the prior authorization program, this code is covered for the FDA‑approved indications.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

90697

Basic benefit and medical policy

Pediatric hexavalent vaccine

The safety and effectiveness of the pediatric hexavalent vaccine (i.e., Vaxelis™) for protection against diphtheria, tetanus, pertussis, poliovirus types 1, 2 and 3, disease caused by Haemophilus influenzae type B (Hib), and hepatitis B (DTaP‑IPV‑Hib‑HepB) is established, effective Dec. 21, 2018.

Payable for all groups covering preventive immunization services.
UPDATES TO PAYABLE PROCEDURES

J9035

Basic benefit and medical policy

Avastin (bevacizumab)

Blue Cross Blue Shield of Michigan has approved payment for the off‑label use of Avastin® (bevacizumab). Procedure code J9035 is payable for off‑label use to treat mesothelioma.

Condition code 90

Condition code 91

Basic benefit and medical policy

Condition codes 90 and 91

The National Uniform Billing Committee approved new condition codes 90 and 91, effective Feb. 1, 2021.
POLICY CLARIFICATIONS

C9254

Basic benefit and medical policy

Vimpat (lacosamide)

Vimpat (lacosamide) is payable for the following updated FDA‑approved indication:

  • Adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures in patients 4 years of age and older.

Dosing information:

  • Adults, aged 17 and older:
    • Initial dosage for monotherapy for the treatment of partial‑onset seizures is 100 mg twice daily.
    • Initial dosage for adjunctive therapy for the treatment of partial‑onset seizures or primary generalized tonic‑clonic seizures is 50 mg twice daily.
    • Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily.
  • Pediatric patients 4 years to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily.
  • Increase dosage based on clinical response and tolerability, no more frequently than once per week.
  • Injection for intravenous use only when oral administration is temporarily not feasible; dosing regimen is the same as oral regimen; administer over 15 to 60 minutes. Obtaining ECG before initiation is recommended in certain patients.
  • Dose adjustment is recommended for severe renal impairment.
  • Dose adjustment is recommended for mild or moderate hepatic impairment; use in patients with severe hepatic impairment isn’t recommended.

J0638

Basic benefit and medical policy

ILARIS

ILARIS is an interleukin‑1β blocker payable for the following FDA‑approved indications:

Periodic fever syndromes

Cryopyrin‑associated periodic syndromes in adults and children 4 years of age and older, including:

  • Familial cold auto‑inflammatory syndrome
  • Muckle‑Wells syndrome
  • Tumor necrosis factor receptor associated periodic syndrome in adult and pediatric patients

Hyperimmunoglobulin D syndrome/Mevalonate Kinase deficiency in adult and pediatric patients

Familial Mediterranean fever in adult and pediatric patients

Active Still’s disease, including adult‑onset Still’s disease and systemic juvenile idiopathic arthritis in patients age 2 years and older

J1602

Basic benefit and medical policy

Simponi Aria (golimumab)

Simponi Aria® (golimumab) is payable for the following
updated FDA‑approved indications:

  • Adult patients with moderately to severely active rheumatoid arthritis in combination with methotrexate
  • Active psoriatic arthritis in patients age 2 years and older
  • Adult patients with active Ankylosing spondylitis
  • Active polyarticular juvenile idiopathic arthritis in patients age 2 years and older.

Dosing information:

  • Adult patients with rheumatoid arthritis, psoriatic arthritis and Ankylosing spondylitis:
    • 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every eight weeks thereafter
  • Pediatric patients with polyarticular juvenile idiopathic arthritis and psoriatic arthritis:
    • 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every eight weeks thereafter
  • Dilution of supplied Simponi Aria solution with 0.9% sodium chloride injection, USP is required prior to administration. Alternatively, 0.45% sodium chloride injection, USP can also be used.

J2182

Basic benefit and medical policy

Nucala (mepolizumab)

Nucala (mepolizumab) is payable for the following updated FDA‑approved indications:

The treatment of adult and pediatric patients age 12 years and older with hypereosinophilic syndrome for greater than six months without an identifiable non-hematologic secondary cause.

Dosing information:

300 mg as three separate 100‑mg injections administered subcutaneously once every four weeks.

J3490

J3590

Basic benefit and medical policy

Fetroja (cefiderocol)

Effective Sept. 28, 2020, Fetroja (cefiderocol) is covered for the following FDA‑approved indications:

Fetroja is a cephalosporin antibacterial indicated in patients age 18 years or older for the treatment of the following infections caused by susceptible Gram‑negative microorganisms:

  • Hospital‑acquired bacterial pneumonia and ventilator‑associated bacterial pneumonia

Dosage information:

  • Administer 2 grams of Fetroja for injection every eight hours by intravenous infusion over three hours in patients with creatinine clearance (CLcr) 60 to 119 mL/min.
  • Dose adjustments are required for patients with CLcr less than 60 mL/min, including patients receiving intermittent hemodialysis or continuous renal replacement therapy, and for patients with CLcr 120 mL/min or greater.

This drug isn’t a benefit for URMBT.

J9145

Basic benefit and medical policy

Darzalex (daratumumab)  

Effective Aug. 20, 2020, Darzalex (daratumumab) is covered for the following FDA‑approved indications: 

Darzalex is a CD38‑directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma:

  • In combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy

Dosage information:

  • Pre‑medicate with corticosteroids, antipyretics and antihistamines
  • Dilute and administer as an intravenous infusion
  • Recommended dose is 16 mg/kg actual body weight. See full prescribing information for drugs used in combination and schedule.
  • Administer post‑infusion medications

Q5113

Basic benefit and medical policy

Herzuma (trastuzumab‑pkrb)

Herzuma (trastuzumab‑pkrb) is payable for the
following new FDA‑approved indication:

  • The treatment of HER2‑overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Dosage information:

For metastatic HER2‑overexpressing gastric cancer,
initial dose of 8 mg/kg over 90‑minute IV infusion, followed by 6 mg/kg over 30 to 90‑minute IV infusion every three weeks.

Pharmacy doesn’t require preauthorization of this drug.

The national drug codes are 63459‑0305‑47 and 63459‑0303‑43.

Occurrence Codes 61 and 62

Payment policy

Occurrence codes 61 and 62

The National Uniform Billing Committee approved new occurrence codes 61 and 62, effective Jan. 1, 2020. 

Value code D6

Payment policy

Value code D6

Blue Cross Blue Shield of Michigan will accept new value code D6, which was approved by the National Uniform Billing Committee, effective January 2021.

What’s included in The Record’s Pharmacy category

We recently received some questions about Record articles included in the newsletter’s Pharmacy category. The Pharmacy category is used for articles pertaining to both pharmacy drugs and medical benefit drugs. Our Pharmacy Services department manages both the pharmacy drug benefit and the medical drug benefit for members.

However, as you know, medical drugs are billed as medical claims because they’re administered by health professionals. Drugs purchased by our members at a pharmacy are billed by the pharmacy that dispenses the drug.

Drug‑related articles also may appear in other categories to reflect where they’re being billed and administered. For example, they may be included in the Professional category or the Facility category or both, depending on whether they’re billed by doctor’s offices, hospitals or both. That’s because we want to be sure that billers know of any changes related to these drugs and how we cover them.

Our Record newsletter is organized by category, including Professional, Facility, Pharmacy, DME and All Providers. The All Providers category is used for articles that are likely to be of interest to all our providers. Each issue of the newsletter doesn’t necessarily include articles in every category.

If you’re not already subscribed, you can subscribe to The Record or other provider newsletters by clicking here. By subscribing, the newsletter will arrive in your email on the last business day of each month.

Professional

We made changes to our Telehealth procedure codes for COVID‑19 chart

We removed certain Current Procedural Terminology codes from the commercial section of our Telehealth procedure codes for COVID‑19 document to better reflect the more general language in our policy on telemedicine. We also removed CPT codes from the Medicare Advantage sections of the document, and are referring providers to the Centers for Medicare & Medicaid Services’ Covered Telehealth Services for PHE for the COVID‑19 pandemic list** for the billable services allowed for our Medicare Advantage members.

To save you the time of having to download the ZIP file from the CMS link above, we provide a PDF of the Medicare‑covered telehealth services list on our website. We review this list monthly and will provide any updates from CMS as necessary. For the most recent Medicare‑covered telehealth services, refer to the list on CMS’ website.

You’ll find the PDF and the following informative documents in the Telehealth section of our COVID‑19 webpages on our public website at bcbsm.com/coronavirus and through Provider Secured Services:

Medicare Advantage cost‑sharing reminder
Effective Jan. 1, 2021, member cost share for Medicare‑covered telehealth services during the COVID‑19 public health emergency is no longer automatically waived. Cost share is now applied based on the patient’s plan coverage guidelines. Check the member’s eligibility and benefits to determine if cost share applies.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


We’ve resolved attribution issue related to COVID‑19 testing

Last year, Blue Cross Blue Shield of Michigan released billing guidelines for COVID‑19 testing in a web‑DENIS alert titled “Billing recommendations for COVID‑19 testing, including drive through.”

In these guidelines, we instructed primary care providers to bill the evaluation and management code *99211 plus the diagnosis code Z20.828 for observing a self-administered specimen collection for COVID‑19 testing in new or established patients.

When *99211 was billed by a primary care physician in an office setting, the event was included in the Blue Cross “attribution algorithm,” which assigns members to a primary care physician. When using this code as part of the algorithm, it was possible for a member to be attributed to a primary care physician when the physician was only testing for COVID‑19.

This issue was brought to our attention, and we subsequently updated our attribution algorithm to exclude any claims that have both the CPT code *99211 and diagnosis code Z20.828.

The update was made before the October membership freeze. All year‑end reporting, including Blueprint for Affordability and value-based reimbursement analytics, will use the corrected attribution algorithm.

January 2021 reporting includes the updated attribution. Previous attribution lists won’t be restated.

Physician organization administrators can submit questions about this issue to the PGIP Collaboration Site, which can be accessed in the provider area of bcbsm.com.


Medical benefit specialty drug prior authorization list changing in April for most members

Starting in April 2021, we’re adding prior authorization requirements for some drugs covered under the medical benefit. Providers must request prior authorization through AIM Specialty Health®.

For dates of service on or after April 15, 2021, the following drug will require prior authorization for UAW Retiree Medical Benefits Trust PPO non-Medicare members:

  • Kanjinti™ (trastuzumab‑anns), HCPCS code Q5117

For dates of service on or after April 22, 2021, the following drugs will require prior authorization for Blue Cross Blue Shield of Michigan commercial fully insured members and for Blue Care Network commercial, Medicare Plus Blue℠ and BCN Advantage℠ members:

  • Danyelza® (naxitamab‑gqgk), HCPCS codes J3490, J3590, J9999, C9399
  • Margenza™ (margetuximab‑cmkb), HCPCS codes J3490, J3590, J9999, C9399

These requirements don’t apply to members of the Blue Cross and Blue Shield Federal Employee Program® and MESSA.

Submit authorization requests to AIM through the AIM provider portal** or by calling the AIM Contact Center at 1‑844‑377‑1278.

For information about registering for and accessing the AIM ProviderPortal, see the Frequently Asked Questions page** on the AIM website.

More about the authorization requirements

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

For more information on requirements related to drugs covered under the medical benefit, see:

We’ll update these lists to reflect these changes prior to the effective dates.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Procedure codes *71271 and *33208 don’t require authorization for most members

Services associated with radiology CPT code *71271 and cardiology CPT code *33208 don’t require authorization for these members:

  • Blue Care Network commercial
  • BCN Advantage℠
  • Medicare Plus Blue℠

We’ve removed these procedure codes from the document, Procedures that require prior authorization by AIM Specialty Health®: Cardiology, radiology (high technology) and sleep studies (in lab).

Additionally, we’ll reprocess and pay any claims related to these procedure codes that we denied for lack of authorization.


We’re planning to update our clinical edits for Medicare Advantage PPO claims

Blue Cross Blue Shield of Michigan Medicare Advantage PPO will update clinical edits applied to claims starting in June or shortly thereafter. We’re enhancing the edits as part of our efforts to promote correct coding for claims.

These improvements will help ensure that our claim payment policies align with nationally recognized sources of information and are easy to understand. They’ll also help us better meet the needs of a changing health care industry while maintaining alignment with national coding guidelines.

MA PPO medical and payment policies will continue to comply with:

  • National coverage determinations
  • General coverage guidelines included in original Medicare manuals and instructions
  • Written coverage decisions of the local Medicare administrative contractor

Some of the enhancements include, but are not limited to:

  • CCI edits
  • Evaluation and Management Services
  • Global surgery period

As with the application of all our clinical edits, the guidelines and regulations of these sources should be followed:

  • Centers for Medicare & Medicaid Services’ medical policies
  • American Medical Association CPT coding guidelines
  • National bundling edits, including the Correct Coding Initiative
  • Modifier usage
  • Global surgery period
  • Add‑on code usage

As the enhancements draw closer, we’ll provide updates.

The appeal process won’t change with the expanded edits, but new edit codes will be published in the coming months. Continue to submit appeals on the Clinical Editing Appeal Form with the necessary supporting documentation. And remember to continue to fax one appeal at a time to avoid processing delays.


eviCore will no longer mail Practice Profile summaries and category information for outpatient physical therapy services starting in July

Beginning with July 2021 data, eviCore will no longer mail paper copies of the Practice Profile Summary, which includes information about your assigned category, to health care providers. Instead, eviCore will post category updates on the first business day of February and August each year beginning in August 2021.

Follow these steps to access your Practice Profile Summary and obtain your category:

  1. Access eviCore’s provider portal and select Practitioner Performance Summary from the main menu.
  2. You may be prompted to select the health plan (select either Blue Cross or BCN) and enter your NPI.    
  3. Click on the View PPS button to review your PPS.
  4. To find out your assigned category, click on the UM Category tab in the top left corner.

If you believe there are circumstances adversely affecting your utilization data, you may still request reconsideration within 15 days of eviCore’s notification. Initiate your reconsideration request within the UM Category window.  

Additional information is available on the evicore.com** website as follows:

  1. From the Implementation Resources page** of evicore.com,** click on the Solution Resources tab.
  2. Click on Musculoskeletal.
  3. Click on Practitioner Performance Summary and Utilization Management Categories Training Presentation.

 You can also contact Provider and Client Services at 1‑800‑646‑0418 for more information.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Optum to handle credit recovery efforts for Blue Cross and BCN

Effective Jan. 1, 2021, Optum® has been assigned to identify and recover credit balance overpayments on behalf of Blue Cross Blue Shield of Michigan and Blue Care Network claims. Previously, these reviews may have been conducted by Conduent, formerly known as CDR Associates. Any review initiated by Conduent that is in progress will be completed by Conduent with an estimated completion date of February 2021.   

Optum conducts periodic claim reviews at provider locations. They’re a professional health care consulting firm that has focused on assisting both providers and payers by identifying and processing credit balances. Reviews only involve patient accounting records, not medical records. Claim recoveries will be handled through claims offset, not check refunds. 

Additionally, claims data will be available through a web-based tool for providers who choose to submit credit balance recoveries through Optum’s overpayment management tool.

Note: For Medicare Plus Blue℠ overpayments, providers may continue to submit a Request for offset of a Medicare Advantage overpayment form directly to Blue Cross using the existing process. This involves identifying the reason for the overpayment of a medical claim paid through IKA. The claim is then adjusted in IKA, resulting in an offset of future claim payments.


Blue Cross and BCN Pharmacy to cover additional childhood vaccines, starting March 1

To increase access to childhood vaccines and decrease the risk of vaccine‑preventable disease outbreaks among children, Blue Cross Blue Shield of Michigan and Blue Care Network Pharmacy Services is adding the following vaccines to its list of covered vaccines, starting March 1, 2021:

Vaccine Common name Age requirement
ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
ProQuad® Measles, mumps, rubella and varicella None
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap-IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and tetanus toxoids Tetanus, diphtheria None

The following lists all the vaccines currently covered under eligible members’ prescription drug plans. Most Blue Cross commercial, non‑Medicare members with prescription drug coverage are eligible. If a member meets the coverage criteria, we cover the vaccine with no cost share.

Vaccine Common name Age requirement
Influenza virus Flu

Under 9 years old:
2 vaccines per 180 days

9 years and older:
1 vaccine per 180 days

ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
Havrix® Hepatitis A None
Vaqta® Hepatitis A None
Energix‑B® Hepatitis B None
Heplisav‑B® Hepatitis B None
Recombivax HB® Hepatitis B None
Twinrix® Hepatitis A & B None
Gardasil®9 HPV (Human papillomavirus) 9 to 45 years old
M‑M‑R® II Measles, mumps, rubella None
ProQuad® Measles, mumps, rubella and varicella None
Menveo® Meningitis None
Menactra® Meningitis None
Menomune® Meningitis None
Trumenba® Meningococcal B None
Bexsero® Meningococcal B None
Ipol® Polio None
Pneumovax 23 Pneumonia None
Prevnar 13® Pneumonia 65 and older
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Shingrix® Shingle (Zoster) 50 and older
Boostrix® Tdap (Tetanus, diphtheria and whooping cough, also known as pertussis) None
Adacel® Tdap None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap‑IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and Tetanus Toxoids Tetanus, diphtheria None
Tenivac® Tetanus, diphtheria None
TDVax® Tetanus, diphtheria None
Varivax® Varicella (chickenpox) None

If a member doesn’t meet the age requirement for a vaccine, Blue Cross won’t cover the vaccine under the prescription drug plan and the claim will reject.

Certified, trained, qualified registered pharmacists must administer vaccines.


We’ve added site‑of‑care requirements for Uplizna for Blue Cross commercial members

Effective Jan. 1, 2021, Blue Cross Blue Shield of Michigan has added site‑of‑care requirements for Uplizna® (inebilizumab‑cdon), HCPCS code J1823. This drug is covered under the medical benefit for our commercial members.

Encourage your patients who have Blue Cross commercial coverage to select one of the following infusion locations instead of using a hospital outpatient facility:

  • A doctor’s office or other health care provider’s office
  • An ambulatory infusion center
  • The member’s home, from a home infusion therapy provider

If members currently receive infusions for these drugs at a hospital outpatient facility, providers must:

  • Obtain prior authorization for receiving the infusion at a hospital outpatient facility location.
  • Check the directory of participating home infusion therapy providers and infusion centers to see where the member can continue receiving infusion therapy. To do this, go to bcbsm.com, click on Find a Doctor, click on the Search without logging in link, click on Places by type, enter Home infusion therapy or Ambulatory infusion therapy center in the search field and press the Enter key.

Override for infusions received from Jan. 1 through Feb. 18
If a member had a prior authorization that didn’t include a site‑of‑care requirement and received an infusion of Uplizna at an outpatient hospital facility from Jan. 1 through Feb. 18, 2021, the claim will be rejected for a noncovered site of care.

However, you can receive an override for these dates of service so the claim will pay. To inquire about an override, call the Pharmacy Clinical Help Desk at 1‑800‑437‑3803.

For dates of service on or after Feb. 19, all members must receive infusions at a covered infusion location, unless the provider obtains prior authorization for receiving the infusion at a hospital outpatient facility location.

More about authorization requirements
These authorization requirements apply only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit.

Note: Uplizna already has site‑of‑care requirements for Blue Care Network commercial members for dates of service on or after Aug. 1, 2020.

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

List of requirements
For requirements related to drugs covered under the medical benefit, review these resources:

Additional information
This change doesn’t apply to:

  • BCN Advantage℠ members
  • Medicare Plus Blue℠ members

Virtual provider symposiums to focus on patient experience, HEDIS, documentation and coding

We’ve tentatively scheduled this year’s provider symposiums virtually throughout May and June for physicians, office staff and coders. Save the dates below and keep in mind that you’ll be able to register for more than one session. We’ll publish the registration links in the April Record.

These sessions are for physicians and office staff responsible for closing gaps in care related to quality measures and creating a positive patient experience:

Topic Date and time
HEDIS® measures (details and exclusions),
Consumer Assessment of Healthcare Providers and Systems Survey,
and Health Outcomes Survey

Tuesday, May 4

Noon to 2 p.m.

 

Wednesday, May 12

8 to 10 a.m.
 

Thursday, May 20

Noon to 2 p.m.
 

Tuesday, June 8

8 to 10 a.m.
 

Wednesday, June 16

Noon to 2 p.m.
 

Thursday, June 24

8 to 10 a.m.
 

 

Patient experience

Tuesday, May 4

8 to 10 a.m.
 

Wednesday, May 5

Noon to 2 p.m.
 

Wednesday, May 12

Noon to 2 p.m.
 

Thursday, May 20
8 to 10 a.m.

 

Tuesday, June 8
Noon to 2 p.m.

 

Wednesday, June 16

8 to 10 a.m.

These sessions are for physicians and office staff responsible for closing gaps in care related to quality measures and creating a positive patient experience:

Topic Date and time
Updates on telehealth, and CPT, ICD‑10‑CM
and evaluation and management codes

Thursday, May 6

8 to 9 a.m.
 

Tuesday, May 11

Noon to 1 p.m.
 

Wednesday, May 19

8 to 9 a.m.
 

Thursday, June 10

Noon to 1 p.m.
 

Tuesday, June 15

8 to 9 a.m.
 

Wednesday, June 23

Noon to 1 p.m.

Nurses and coders can receive continuing education credits for attending the sessions.

HEDIS® is a registered trademark of the National Committee for Quality Assurance.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

Sign up now for live, monthly, lunchtime webinars focusing on risk adjustment and coding. Starting in April, these educational sessions will update you on documentation and coding of common challenging diagnoses. You’ll also have an opportunity to ask questions.

April through September’s webinars are led by physicians. The last three sessions of the year focus on coding guideline updates and are led by coders.

While the session topics could change, our current schedule and tentative topics follow. All sessions start at 12:15 p.m. Eastern time and generally run for 15 to 30 minutes. Click on a Register here link below to sign up for a session.

Session date Topic Sign‑up link
Tuesday, April 20 Acute conditions reported in the outpatient setting Register here
Wednesday, May 19 Morbid (severe) obesity Register here
Thursday, June 17 Major depression Register here
Tuesday, July 20 Diabetes with complications Register here
Wednesday, Aug. 18 Renal disease Register here
Thursday, Sept. 23 Malignant neoplasm Register here
Tuesday, Oct. 12 Updates for ICD‑10‑CM Register here
Wednesday, Nov. 17 Coding scenarios for primary care and specialty Register here
Thursday, Dec. 9 E/M coding tips Register here

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


Reminder: Sign up for additional training webinars

Provider Experience is continuing its series of training webinars for health care providers and staff. The webinars are designed to help you work more efficiently with Blue Cross Blue Shield of Michigan and Blue Care Network.

Here’s information on the upcoming training webinars:

Webinar name Date and time Registration
Blue Cross 201 – Claims Basics – Professional

Tuesday, March 2, 2021

10 to 11 a.m.
Click here to register.
Blue Cross 201 – Claims Basics – Professional

Tuesday, March 2, 2021

2 to 3 p.m.
Click here to register.

The Blue Cross 201 webinar series provides an in‑depth learning opportunity and builds on information shared in our Blue Cross 101: Understanding the Basics webinar. This session reviews the processes and tools available when submitting professional claims.

Recordings of previous webinars are available on web‑DENIS through the Blue Cross Provider Publications and Resources or BCN Provider Publications and Resources pages as follows:

Blue Cross Provider Publications and Resources

  1. Log in to Provider Secured Services.
  2. Click on BCBSM Provider Publications and Resources.
  3. Click on BCBSM Newsletters and Resources.
  4. Click on Provider Training.
  5. In the Featured Links section of the page, check out 2020 Provider Training Webinars.

You can also get more information about online training, presentations and videos by clicking on the E‑Learning icon at the top of the page.

BCN Provider Publications and Resources

  1. Log in to Provider Secured Services.
  2. Go to BCN Provider Publications and Resources.
  3. Under Other Resources, click on Learning Opportunities.
  4. Find the most recent webinars under 2020 Provider Training Webinars.

As additional training webinars become available, we’ll provide notices through web‑DENIS, The Record and BCN Provider News.


Reminder: Refer Blue Cross FEP members to Blue Cross Blue Shield of Michigan network providers

When Blue Cross and Blue Shield Federal Employee Program® members are referred to out‑of‑network providers, they’re at risk of having to pay higher costs. Be sure to follow the directions in your Blue Cross Blue Shield of Michigan provider agreement and Blue Cross provider manual, instructing you to refer your Blue Cross patients to network providers.

Our goal is to:

  • Give members convenient access to high‑quality, cost‑efficient services that meet their clinical needs.
  • Help members avoid higher copayments and other out‑of‑pocket costs that may result from using out‑of‑network providers.

To verify if a provider is in the Blue Cross network for your patient, visit bcbsm.com or click here.


Follow‑up care key after ER visit for mental health issues, substance use disorder

According to the National Committee for Quality Assurance, when a patient is discharged from an emergency room for mental health issues** or substance use disorder,** follow‑up visits with a doctor help to:

  • Reduce medication errors.
  • Improve mental and physical function.
  • Increase compliance with follow-up instructions.
  • Decrease substance use.
  • Reduce repeat ER visits and hospital admissions.

Follow‑up care can be in the doctor’s office, online or by phone. To assist members in their recovery, the Blue Cross and Blue Shield Federal Employee Program® offers additional services to support members:

  • New Directions Behavioral Health Mental health and substance use disorder case management
    Phone: 1‑800‑342‑5891
  • Coordinated Care Program — Assistance in coordinating services to manage health conditions
    Phone: 1‑800‑775‑2583
  • 24/7 Nurse Line — General questions about health issues, medications or where to go for care
    Phone: 1‑888‑258‑3432
    Online: www.fepblue.org/myblue
  • Telehealth services — Members can speak to a behavioral health specialist or board-certified doctor
    Phone: 1‑855‑636‑1579
    Online: www.fepblue.org/telehealth
  • Personal Health Record — Members with a MyBlue® account can keep track of appointments and medications
    Online: www.fepblue.org/myblue
  • Customer Service — Assistance to find a Preferred primary care doctor, psychiatrist, psychologist or other specialty provider and benefit information
    Phone: 1‑800‑482‑3600
    Online: vwww.fepblue.org/provider

New Directions is an independent company contracted by Blue Cross Blue Shield of Michigan to perform mental health and substance us disorder case management services for FEP Service Benefit Plan members.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.

Facility

How to submit appeals of Medicare Advantage inpatient acute care admissions

Providers who need to submit appeals for denied authorization requests for Medicare Plus Blue℠ and BCN Advantage℠ inpatient acute care admissions (non‑behavioral health) should follow the process described in the provider manuals. Instructions can also be found in the denial letters Blue Cross Blue Shield of Michigan or Blue Care Network send providers.

Medicare Plus Blue

For Medicare Plus Blue members, providers can find the process in the “Contracted MI Provider Acute Inpatient Admission Appeals” section of the Medicare Plus Blue℠ PPO Provider Manual.

Here’s a screenshot:

Inpatient Admission Appeals Screenshot 1

Inpatient Admission Appeals Screenshot 1

BCN Advantage

For BCN Advantage members, providers can find instructions in the “Utilization Management” chapter of the BCN Provider Manual. Look in the section titled “Appealing utilization management decisions.”

Here’s a screenshot:

Appealing utilzation management decisions screenshot 1

Appealing utilzation management decisions screenshot 2


Don’t use F codes when requesting authorization for Medicare Advantage inpatient medical admissions

When requesting authorization for acute care inpatient medical (non‑behavioral health) admissions, select a medical ICD‑10 diagnosis code in the e-referral system — one that doesn’t begin with F.

If you select an ICD‑10 diagnosis code that begins with F, the processing of your request will be delayed because:

  • You’ll trigger a behavioral health questionnaire that you must complete.
  • Your request will be routed to the incorrect department for review.

Background

We’ve noticed that for members admitted to a medical unit for acute detoxification (such as withdrawal from alcohol or other drugs), providers are sometimes submitting authorization requests with diagnosis codes that begin with F.

However, these are considered medical — not behavioral health — admissions, even though the member’s condition involves the use of alcohol or other substances.

Members this applies to

This applies to members covered by these plans:

  • Medicare Plus Blue℠
  • BCN Advantage℠

Medical benefit specialty drug prior authorization list changing in April for most members

Starting in April 2021, we’re adding prior authorization requirements for some drugs covered under the medical benefit. Providers must request prior authorization through AIM Specialty Health®.

For dates of service on or after April 15, 2021, the following drug will require prior authorization for UAW Retiree Medical Benefits Trust PPO non-Medicare members:

  • Kanjinti™ (trastuzumab‑anns), HCPCS code Q5117

For dates of service on or after April 22, 2021, the following drugs will require prior authorization for Blue Cross Blue Shield of Michigan commercial fully insured members and for Blue Care Network commercial, Medicare Plus Blue℠ and BCN Advantage℠ members:

  • Danyelza® (naxitamab‑gqgk), HCPCS codes J3490, J3590, J9999, C9399
  • Margenza™ (margetuximab‑cmkb), HCPCS codes J3490, J3590, J9999, C9399

These requirements don’t apply to members of the Blue Cross and Blue Shield Federal Employee Program® and MESSA.

Submit authorization requests to AIM through the AIM provider portal** or by calling the AIM Contact Center at 1‑844‑377‑1278.

For information about registering for and accessing the AIM ProviderPortal, see the Frequently Asked Questions page** on the AIM website.

More about the authorization requirements

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

For more information on requirements related to drugs covered under the medical benefit, see:

We’ll update these lists to reflect these changes prior to the effective dates.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Procedure codes *71271 and *33208 don’t require authorization for most members

Services associated with radiology CPT code *71271 and cardiology CPT code *33208 don’t require authorization for these members:

  • Blue Care Network commercial
  • BCN Advantage℠
  • Medicare Plus Blue℠

We’ve removed these procedure codes from the document, Procedures that require prior authorization by AIM Specialty Health®: Cardiology, radiology (high technology) and sleep studies (in lab).

Additionally, we’ll reprocess and pay any claims related to these procedure codes that we denied for lack of authorization.


We’re planning to update our clinical edits for Medicare Advantage PPO claims

Blue Cross Blue Shield of Michigan Medicare Advantage PPO will update clinical edits applied to claims starting in June or shortly thereafter. We’re enhancing the edits as part of our efforts to promote correct coding for claims.

These improvements will help ensure that our claim payment policies align with nationally recognized sources of information and are easy to understand. They’ll also help us better meet the needs of a changing health care industry while maintaining alignment with national coding guidelines.

MA PPO medical and payment policies will continue to comply with:

  • National coverage determinations
  • General coverage guidelines included in original Medicare manuals and instructions
  • Written coverage decisions of the local Medicare administrative contractor

Some of the enhancements include, but are not limited to:

  • CCI edits
  • Evaluation and Management Services
  • Global surgery period

As with the application of all our clinical edits, the guidelines and regulations of these sources should be followed:

  • Centers for Medicare & Medicaid Services’ medical policies
  • American Medical Association CPT coding guidelines
  • National bundling edits, including the Correct Coding Initiative
  • Modifier usage
  • Global surgery period
  • Add‑on code usage

As the enhancements draw closer, we’ll provide updates.

The appeal process won’t change with the expanded edits, but new edit codes will be published in the coming months. Continue to submit appeals on the Clinical Editing Appeal Form with the necessary supporting documentation. And remember to continue to fax one appeal at a time to avoid processing delays.


eviCore will no longer mail Practice Profile summaries and category information for outpatient physical therapy services starting in July

Beginning with July 2021 data, eviCore will no longer mail paper copies of the Practice Profile Summary, which includes information about your assigned category, to health care providers. Instead, eviCore will post category updates on the first business day of February and August each year beginning in August 2021.

Follow these steps to access your Practice Profile Summary and obtain your category:

  1. Access eviCore’s provider portal and select Practitioner Performance Summary from the main menu.
  2. You may be prompted to select the health plan (select either Blue Cross or BCN) and enter your NPI.    
  3. Click on the View PPS button to review your PPS.
  4. To find out your assigned category, click on the UM Category tab in the top left corner.

If you believe there are circumstances adversely affecting your utilization data, you may still request reconsideration within 15 days of eviCore’s notification. Initiate your reconsideration request within the UM Category window.  

Additional information is available on the evicore.com** website as follows:

  1. From the Implementation Resources page** of evicore.com,** click on the Solution Resources tab.
  2. Click on Musculoskeletal.
  3. Click on Practitioner Performance Summary and Utilization Management Categories Training Presentation.

 You can also contact Provider and Client Services at 1‑800‑646‑0418 for more information.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Optum to handle credit recovery efforts for Blue Cross and BCN

Effective Jan. 1, 2021, Optum® has been assigned to identify and recover credit balance overpayments on behalf of Blue Cross Blue Shield of Michigan and Blue Care Network claims. Previously, these reviews may have been conducted by Conduent, formerly known as CDR Associates. Any review initiated by Conduent that is in progress will be completed by Conduent with an estimated completion date of February 2021.   

Optum conducts periodic claim reviews at provider locations. They’re a professional health care consulting firm that has focused on assisting both providers and payers by identifying and processing credit balances. Reviews only involve patient accounting records, not medical records. Claim recoveries will be handled through claims offset, not check refunds. 

Additionally, claims data will be available through a web-based tool for providers who choose to submit credit balance recoveries through Optum’s overpayment management tool.

Note: For Medicare Plus Blue℠ overpayments, providers may continue to submit a Request for offset of a Medicare Advantage overpayment form directly to Blue Cross using the existing process. This involves identifying the reason for the overpayment of a medical claim paid through IKA. The claim is then adjusted in IKA, resulting in an offset of future claim payments.


We’ve added site‑of‑care requirements for Uplizna for Blue Cross commercial members

Effective Jan. 1, 2021, Blue Cross Blue Shield of Michigan has added site‑of‑care requirements for Uplizna® (inebilizumab‑cdon), HCPCS code J1823. This drug is covered under the medical benefit for our commercial members.

Encourage your patients who have Blue Cross commercial coverage to select one of the following infusion locations instead of using a hospital outpatient facility:

  • A doctor’s office or other health care provider’s office
  • An ambulatory infusion center
  • The member’s home, from a home infusion therapy provider

If members currently receive infusions for these drugs at a hospital outpatient facility, providers must:

  • Obtain prior authorization for receiving the infusion at a hospital outpatient facility location.
  • Check the directory of participating home infusion therapy providers and infusion centers to see where the member can continue receiving infusion therapy. To do this, go to bcbsm.com, click on Find a Doctor, click on the Search without logging in link, click on Places by type, enter Home infusion therapy or Ambulatory infusion therapy center in the search field and press the Enter key.

Override for infusions received from Jan. 1 through Feb. 18
If a member had a prior authorization that didn’t include a site‑of‑care requirement and received an infusion of Uplizna at an outpatient hospital facility from Jan. 1 through Feb. 18, 2021, the claim will be rejected for a noncovered site of care.

However, you can receive an override for these dates of service so the claim will pay. To inquire about an override, call the Pharmacy Clinical Help Desk at 1‑800‑437‑3803.

For dates of service on or after Feb. 19, all members must receive infusions at a covered infusion location, unless the provider obtains prior authorization for receiving the infusion at a hospital outpatient facility location.

More about authorization requirements
These authorization requirements apply only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit.

Note: Uplizna already has site‑of‑care requirements for Blue Care Network commercial members for dates of service on or after Aug. 1, 2020.

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

List of requirements
For requirements related to drugs covered under the medical benefit, review these resources:

Additional information
This change doesn’t apply to:

  • BCN Advantage℠ members
  • Medicare Plus Blue℠ members

Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

Sign up now for live, monthly, lunchtime webinars focusing on risk adjustment and coding. Starting in April, these educational sessions will update you on documentation and coding of common challenging diagnoses. You’ll also have an opportunity to ask questions.

April through September’s webinars are led by physicians. The last three sessions of the year focus on coding guideline updates and are led by coders.

While the session topics could change, our current schedule and tentative topics follow. All sessions start at 12:15 p.m. Eastern time and generally run for 15 to 30 minutes. Click on a Register here link below to sign up for a session.

Session date Topic Sign‑up link
Tuesday, April 20 Acute conditions reported in the outpatient setting Register here
Wednesday, May 19 Morbid (severe) obesity Register here
Thursday, June 17 Major depression Register here
Tuesday, July 20 Diabetes with complications Register here
Wednesday, Aug. 18 Renal disease Register here
Thursday, Sept. 23 Malignant neoplasm Register here
Tuesday, Oct. 12 Updates for ICD‑10‑CM Register here
Wednesday, Nov. 17 Coding scenarios for primary care and specialty Register here
Thursday, Dec. 9 E/M coding tips Register here

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding registration, email Patricia Scarlett at pscarlett@bcbsm.com.


Reminder: Sign up for additional training webinars

Provider Experience is continuing its series of training webinars for health care providers and staff. The webinars are designed to help you work more efficiently with Blue Cross Blue Shield of Michigan and Blue Care Network.

Here’s information on the upcoming training webinars:

Webinar name Date and time Registration
Blue Cross 201 – Claims Basics – Professional

Tuesday, March 2, 2021

10 to 11 a.m.
Click here to register.
Blue Cross 201 – Claims Basics – Professional

Tuesday, March 2, 2021

2 to 3 p.m.
Click here to register.

The Blue Cross 201 webinar series provides an in‑depth learning opportunity and builds on information shared in our Blue Cross 101: Understanding the Basics webinar. This session reviews the processes and tools available when submitting professional claims.

Recordings of previous webinars are available on web‑DENIS through the Blue Cross Provider Publications and Resources or BCN Provider Publications and Resources pages as follows:

Blue Cross Provider Publications and Resources

  1. Log in to Provider Secured Services.
  2. Click on BCBSM Provider Publications and Resources.
  3. Click on BCBSM Newsletters and Resources.
  4. Click on Provider Training.
  5. In the Featured Links section of the page, check out 2020 Provider Training Webinars.

You can also get more information about online training, presentations and videos by clicking on the E‑Learning icon at the top of the page.

BCN Provider Publications and Resources

  1. Log in to Provider Secured Services.
  2. Go to BCN Provider Publications and Resources.
  3. Under Other Resources, click on Learning Opportunities.
  4. Find the most recent webinars under 2020 Provider Training Webinars.

As additional training webinars become available, we’ll provide notices through web‑DENIS, The Record and BCN Provider News.

Pharmacy

Medical benefit specialty drug prior authorization list changing in April for most members

Starting in April 2021, we’re adding prior authorization requirements for some drugs covered under the medical benefit. Providers must request prior authorization through AIM Specialty Health®.

For dates of service on or after April 15, 2021, the following drug will require prior authorization for UAW Retiree Medical Benefits Trust PPO non-Medicare members:

  • Kanjinti™ (trastuzumab‑anns), HCPCS code Q5117

For dates of service on or after April 22, 2021, the following drugs will require prior authorization for Blue Cross Blue Shield of Michigan commercial fully insured members and for Blue Care Network commercial, Medicare Plus Blue℠ and BCN Advantage℠ members:

  • Danyelza® (naxitamab‑gqgk), HCPCS codes J3490, J3590, J9999, C9399
  • Margenza™ (margetuximab‑cmkb), HCPCS codes J3490, J3590, J9999, C9399

These requirements don’t apply to members of the Blue Cross and Blue Shield Federal Employee Program® and MESSA.

Submit authorization requests to AIM through the AIM provider portal** or by calling the AIM Contact Center at 1‑844‑377‑1278.

For information about registering for and accessing the AIM ProviderPortal, see the Frequently Asked Questions page** on the AIM website.

More about the authorization requirements

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

For more information on requirements related to drugs covered under the medical benefit, see:

We’ll update these lists to reflect these changes prior to the effective dates.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Blue Cross and BCN Pharmacy to cover additional childhood vaccines, starting March 1

To increase access to childhood vaccines and decrease the risk of vaccine‑preventable disease outbreaks among children, Blue Cross Blue Shield of Michigan and Blue Care Network Pharmacy Services is adding the following vaccines to its list of covered vaccines, starting March 1, 2021:

Vaccine Common name Age requirement
ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
ProQuad® Measles, mumps, rubella and varicella None
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap-IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and tetanus toxoids Tetanus, diphtheria None

The following lists all the vaccines currently covered under eligible members’ prescription drug plans. Most Blue Cross commercial, non‑Medicare members with prescription drug coverage are eligible. If a member meets the coverage criteria, we cover the vaccine with no cost share.

Vaccine Common name Age requirement
Influenza virus Flu

Under 9 years old:
2 vaccines per 180 days

9 years and older:
1 vaccine per 180 days

ActHIB® Haemophilus influenzae type B None
Hiberix® Haemophilus influenzae type B None
PedvaxHIB® Haemophilus influenzae type B None
Havrix® Hepatitis A None
Vaqta® Hepatitis A None
Energix‑B® Hepatitis B None
Heplisav‑B® Hepatitis B None
Recombivax HB® Hepatitis B None
Twinrix® Hepatitis A & B None
Gardasil®9 HPV (Human papillomavirus) 9 to 45 years old
M‑M‑R® II Measles, mumps, rubella None
ProQuad® Measles, mumps, rubella and varicella None
Menveo® Meningitis None
Menactra® Meningitis None
Menomune® Meningitis None
Trumenba® Meningococcal B None
Bexsero® Meningococcal B None
Ipol® Polio None
Pneumovax 23 Pneumonia None
Prevnar 13® Pneumonia 65 and older
Rotarix® Rotavirus None
RotaTeq® Rotavirus None
Shingrix® Shingle (Zoster) 50 and older
Boostrix® Tdap (Tetanus, diphtheria and whooping cough, also known as pertussis) None
Adacel® Tdap None
Vaxelis™ Tdap, inactivated poliovirus, haemophilus B, hepatitis B None
Pediarix® Tdap, hepatitis B, polio None
Kinrix® Tdap, polio None
Quadracel® Tdap‑IPV Tdap, polio None
Pentacel® Tdap, polio, haemophilus influenzae type B None
Diptheria and Tetanus Toxoids Tetanus, diphtheria None
Tenivac® Tetanus, diphtheria None
TDVax® Tetanus, diphtheria None
Varivax® Varicella (chickenpox) None

If a member doesn’t meet the age requirement for a vaccine, Blue Cross won’t cover the vaccine under the prescription drug plan and the claim will reject.

Certified, trained, qualified registered pharmacists must administer vaccines.


We’ve added site‑of‑care requirements for Uplizna for Blue Cross commercial members

Effective Jan. 1, 2021, Blue Cross Blue Shield of Michigan has added site‑of‑care requirements for Uplizna® (inebilizumab‑cdon), HCPCS code J1823. This drug is covered under the medical benefit for our commercial members.

Encourage your patients who have Blue Cross commercial coverage to select one of the following infusion locations instead of using a hospital outpatient facility:

  • A doctor’s office or other health care provider’s office
  • An ambulatory infusion center
  • The member’s home, from a home infusion therapy provider

If members currently receive infusions for these drugs at a hospital outpatient facility, providers must:

  • Obtain prior authorization for receiving the infusion at a hospital outpatient facility location.
  • Check the directory of participating home infusion therapy providers and infusion centers to see where the member can continue receiving infusion therapy. To do this, go to bcbsm.com, click on Find a Doctor, click on the Search without logging in link, click on Places by type, enter Home infusion therapy or Ambulatory infusion therapy center in the search field and press the Enter key.

Override for infusions received from Jan. 1 through Feb. 18
If a member had a prior authorization that didn’t include a site‑of‑care requirement and received an infusion of Uplizna at an outpatient hospital facility from Jan. 1 through Feb. 18, 2021, the claim will be rejected for a noncovered site of care.

However, you can receive an override for these dates of service so the claim will pay. To inquire about an override, call the Pharmacy Clinical Help Desk at 1‑800‑437‑3803.

For dates of service on or after Feb. 19, all members must receive infusions at a covered infusion location, unless the provider obtains prior authorization for receiving the infusion at a hospital outpatient facility location.

More about authorization requirements
These authorization requirements apply only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit.

Note: Uplizna already has site‑of‑care requirements for Blue Care Network commercial members for dates of service on or after Aug. 1, 2020.

Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

List of requirements
For requirements related to drugs covered under the medical benefit, review these resources:

Additional information
This change doesn’t apply to:

  • BCN Advantage℠ members
  • Medicare Plus Blue℠ members

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2020 American Medical Association. All rights reserved.